Biostage, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Junli He
- Full Time Employees
- 7
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 84 October Hill Road Holliston MA United States of America 01746
- IPO Date
- Oct 21, 2013
- CIK
- 0001563665
- Website
- biostage.com
- Similar Companies
- Business
- Biostage, Inc. (OTCQB: BSTG) is a clinical-stage biotechnology company that develops bioengineered organ implants using proprietary Cellframe technology, which combines patient-derived stem cells grown on biocompatible scaffolds to regenerate damaged tissue in the esophagus, trachea, and bronchus; its lead product candidate, the Biostage Esophageal Implant or Neo-Esophagus, targets life-threatening conditions such as esophageal cancer, congenital defects, trauma, and birth defects, while earlier-stage programs focus on airway reconstruction for bronchial and tracheal disorders. The company, spun off from Harvard Bioscience in 2013 and formerly known as Harvard Apparatus Regenerative Technology, Inc., changed its name to Biostage in 2016 before reverting to Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) in July 2023 to reflect its regenerative medicine focus. Headquartered in Holliston, Massachusetts, and founded in 2009, Biostage operates primarily in the United States through collaborations with leading institutions including Mayo Clinic and the University of Michigan, where it activated Phase 1 clinical trial sites in 2023 for its esophageal implant following FDA IND clearance, marking its transition to clinical-stage development with no reported recent acquisitions, funding rounds, or partnerships as of late 2025.
Contrasting Defiance Daily Target 2X Long LMND ETF (NASDAQ:LMNX) & Biostage (OTCMKTS:BSTG)
Financial Analysis: Biostage (OTCMKTS:BSTG) and T2 Biosystems (NASDAQ:TTOO)
Critical Comparison: Arch Therapeutics (OTCMKTS:ARTH) vs. Biostage (OTCMKTS:BSTG)
Biostage Activated Mayo Clinic as The First Site for Clinical Trial in Severe Esophageal Disease
Biostage Selects IQVIA to Manage its FDA-Approved Clinical Trial in Severe Esophageal Disease, including Cancer
Biostage, Inc. (BSTG) Q3 2022 Earnings Call Transcript
Biostage Schedules Conference Call and Webcast for Q2 2022 Results
Biostage Begins U.S. Uplisting IPO Rollout
Biostage, Inc. (BSTG) Interim CEO David Green on Q1 2022 Results - Earnings Call Transcript
Biostage Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2021 Financial Results
Biostage Reports Q2 2021 Financial Results
Biostage Reports Q1 2021 Financial Results